Enliven Therapeutics Inc. (NASDAQ:ELVN) — Market Cap & Net Worth
Market Cap & Net Worth: Enliven Therapeutics Inc. (ELVN)
Enliven Therapeutics Inc. (NASDAQ:ELVN) has a market capitalization of $2.46 Billion ($2.46 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5420 globally and #1792 in its home market, demonstrating a 3.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enliven Therapeutics Inc.'s stock price $54.81 by its total outstanding shares 60904946 (60.90 Million). Review Enliven Therapeutics Inc. (ELVN) financial obligations to assess the company's total debt and financial obligations.
Enliven Therapeutics Inc. Market Cap History: 2020 to 2026
Enliven Therapeutics Inc.'s market capitalization history from 2020 to 2026. Data shows change from $5.37 Billion to $3.34 Billion (-1.41% CAGR).
Index Memberships
Enliven Therapeutics Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.10% | #139 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #617 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.14% | #89 of 263 |
Weight: Enliven Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enliven Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enliven Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ELVN by Market Capitalization
Companies near Enliven Therapeutics Inc. in the global market cap rankings as of August 1, 2026.
Key companies related to Enliven Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Enliven Therapeutics Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Enliven Therapeutics Inc.'s market cap moved from $5.37 Billion to $ 3.34 Billion, with a yearly change of -1.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.34 Billion | +255.91% |
| 2025 | $937.94 Million | -31.56% |
| 2024 | $1.37 Billion | +62.57% |
| 2023 | $842.92 Million | -15.40% |
| 2022 | $996.40 Million | +81.78% |
| 2021 | $548.14 Million | -89.80% |
| 2020 | $5.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Enliven Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.46 Billion USD |
| MoneyControl | $2.46 Billion USD |
| MarketWatch | $2.46 Billion USD |
| marketcap.company | $2.46 Billion USD |
| Reuters | $2.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more